colorectal cancerEGFRepidermal growth factor receptorBACKGROUND: Advances in the understanding of tumor biology have led to the development of targeted therapies allowing progress in colorectal cancer treatment. One of the most promising targets is the epidermal growth factor receptor (EGFR). METHOD: ...
拉罗替尼除了在多癌种的治疗中表现优异,近日在2024年美国临床肿瘤学会年会胃肠肿瘤研讨会(ASCO GI)上,也展示了治疗NTRK融合阳性胃肠道癌患者的最新研究数据,效果格外惊艳! 截图源自Colorectal Cancer杂志 根据2 期篮子试验NAVIGATE的最新...
近日，西班牙巴塞罗那瓦尔德西布伦大学医院Elena Elez和西班牙瓦尔德希布伦肿瘤研究所Rodrigo A. T oledo团队共同合作在Nature Medicine上发表题为RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer的研究论文，发现RNF43突变可以预示亚型为微卫星稳定的BRAF...
we analyze how a common oncogenic KRAS mutation (KRASG13D) affects PPIN structure and function of the Epidermal Growth Factor Receptor (EGFR) network in colorectal cancer (CRC
近日,西班牙巴塞罗那瓦尔德西布伦大学医院Elena Elez和西班牙瓦尔德希布伦肿瘤研究所Rodrigo A. T oledo团队共同合作在Nature Medicine上发表题为RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600Emetastatic...
BACKGROUND: Advances in the understanding of tumor biology have led to the development of targeted therapies allowing progress in colorectal cancer treatment. One of the most promising targets is the epidermal growth factor receptor (EGFR). METHOD: The presence and distribution of high- and low-aff...
改善患者筛选、提高针对EGFR通路的现有治疗疗效，以及开发新的联合策略，是目前克服转移性结直肠癌抗药性的重要挑战。2024年4月，《The Lancet Gastroenterology & Hepatology》杂志发表了题为《Targeting the EGFR signalling pathway in metastatic colorectal cancer》一文，深入探讨了表皮生长因子受体（EGFR）信号通路在结...
[2]Luu L J,Price T J.BRAF Mutation and Its Importance in Colorectal Cancer[M]//Advances in the Molecular Understanding of Colorectal Cancer.IntechOpen,2019. [3]Jones J C,Renfro L A,Al-Shamsi H O,et al.Non-V600BRAF mutations define a clinically distinct molecular subtype of metastatic col...
New classes of drugs that target the epidermal growth factor receptor are among the most clinically advanced molecular-targeted therapies and have shown efficacy in colorectal cancer. The current status of epidermal growth factor receptor-targeted therapeutic agents is reviewed, with emphasis on their ...
Cetuximab has been shown to be active as well as single agent as in combination with irinotecan in patients with chemorefractory metastatic colorectal cancer [1]. Panitumumab has been shown to be active as single agent in chemorefractory mCRC [2]. The activity of cetuximab in combination with ...